title: Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy.
abstract: OBJECTIVE
  To evaluate the functional outcomes of patients with polypoidal choroidal vasculopathy (PCV) who underwent intravitreal ranibizumab (IVR) treatment, compared with photodynamic therapy (PDT), after at least 2 years.
  
  
  METHODS
  We retrospectively studied all the treatment-naïve patients with PCV who were scheduled to undergo IVR or PDT between August 2005 and June 2010. All the patients who had a 2-year or longer follow-up period were included in the study. The best-corrected visual acuity (BCVA) in the two groups was compared before treatment and at 3, 6, 12, 18 and 24 months after the initial treatment. The regression of the polyps was also assessed using indocyanine green angiography.
  
  
  RESULTS
  A total of 77 patients were included in this study. Thirty-three eyes were treated with IVR, and 44 eyes were treated with PDT. Although no significant differences between the two groups were observed at baseline or at 3, 6, and 12 months after treatment, a significantly better BCVA was seen in the IVR group, compared with the PDT group, at 18 and 24 months after treatment (P=0.035 and P=0.021, respectively). No significant difference in the rate of polyp regression was observed between the two groups (P=0.092).
  
  
  CONCLUSIONS
  IVR was well tolerated and maintained or improved the vision of patients with PCV, compared with PDT, as evaluated at 2-year follow-up examinations. PDT for the treatment of PCV might result in unfavorable outcomes, with no superiority to achieving the involution of polyps.
authors: Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan.
authors: M
authors: M
authors: Inoue
authors: A
authors: A
authors: Arakawa
authors: S
authors: S
authors: Yamane
authors: K
authors: K
authors: Kadonosono
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D002829:Choroid / Q000098:blood supply; D015862:Choroid Diseases / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000188:drug therapy* / Q000503:physiopathology; D010778:Photochemotherapy; D011127:Polyps / Q000188:drug therapy*; D000069579:Ranibizumab; D012189:Retrospective Studies; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab
references: Arch Ophthalmol. 2003 Oct;121(10):1392-6
references: 14557174
references: Jpn J Ophthalmol. 2011 Jan;55(1):39-44
references: 21331691
references: Retina. 1990;10(1):1-8
references: 1693009
references: Ophthalmologica. 2011;226(3):145-50
references: 21811052
references: Am J Ophthalmol. 2012 Aug;154(2):355-365.e1
references: 22541658
references: Retina. 2002 Oct;22(5):529-35
references: 12441716
references: Arch Ophthalmol. 1997 Apr;115(4):478-85
references: 9109756
references: Retina. 2010 Oct;30(9):1376-85
references: 20683380
references: Am J Ophthalmol. 2012 Jan;153(1):68-80.e1
references: 21907965
references: Am J Ophthalmol. 2010 Jul;150(1):48-54.e1
references: 20609707
references: N Engl J Med. 2006 Oct 5;355(14):1419-31
references: 17021318
references: Retina. 2007 Mar;27(3):335-41
references: 17460589
references: Br J Ophthalmol. 2001 Sep;85(9):1086-91
references: 11520762
references: Am J Ophthalmol. 2012 Jul;154(1):117-124.e1
references: 22465366
references: Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4473-80
references: 14507895
references: Ophthalmology. 2008 Jan;115(1):141-6
references: 17582498
references: Retina. 2010 Sep;30(8):1197-205
references: 20827139
references: Arch Ophthalmol. 1999 Oct;117(10):1329-45
references: 10532441
references: Retina. 2011 Mar;31(3):464-74
references: 20948458
references: Am J Ophthalmol. 2008 Oct;146(4):513-519
references: 18614133
references: Jpn J Ophthalmol. 2007 Jul-Aug;51(4):270-7
references: 17660987
references: Br J Ophthalmol. 2010 Mar;94(3):297-301
references: 19726427
references: Ophthalmology. 2004 Aug;111(8):1576-84
references: 15288991
references: Am J Ophthalmol. 2002 May;133(5):639-48
references: 11992861
references: Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):277-84
references: 19485292
references: Ophthalmologica. 2004 May-Jun;218(3):193-201
references: 15103216
references: Retina. 2012 Sep;32(8):1453-64
references: 22426346
references: Retina. 2012 Jul;32(7):1272-9
references: 22547209
references: Ophthalmologica. 2011;226(4):205-13
references: 21893965